Author

Michelle Luo 1

1 Takeda Pharmaceuticals, Chicago, United States of America

PATTERNS OF DOSE ESCALATION AMONGST PATIENTS WITH ULCERATIVE COLITIS AND CROHN?S DISEASE TREATED WITH VEDOLIZUMAB VS. INFLIXIMAB IN THE UNITED STATES (US)

Mireia Raluy Callado, Qian Li, Michelle Luo, Karen Lasch, Javaria Mona Khalid

SIMPLIFIED RULES TO IDENTIFY BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE WITH HIGHER LIKELIHOOD OF CLINICAL REMISSION WHEN INITIATING VEDOLIZUMAB VERSUS ANTI-TNF THERAPIES: ANALYSIS OF EVOLVE STUDY DATA

Gerassimos J. Mantzaris, Andres Yarur, Annie Guerin, Pravin Kamble, Michelle Luo, Song Wang, Ha Nguyen, Emma Billmyer, Brian Bressler, Shashi Adsul

Item 1 - 2 / 2
1